Genome sequencing group Illumina on March 15 launched a cancer test in Europe that checks for a wide range of tumor genes in one tissue sample, potentially helping patients with rare diseases to be matched up with treatment options.

Biosimilar development continues to advance for the U.S. market in anticipation of becoming an alternative to a brand drug with similar safety and efficacy.

Novavax Inc. announced the launch of the biotechnology company’s global unbranded ‘We Do Vaccines’ and ‘Know Our Vax’ programs, educational efforts aimed to help protect the health of people everywhere in the fight against COVID-19 and other deadly infectious diseases, such as influenza.

Bristol Myers Squibb’s blockbuster cancer drug Revlimid finally has a competitor as Teva Pharmaceuticals announced the launch of a generic version of Revlimid, which could significantly cut into the global biopharmaceutical company’s earnings.

Cosette Pharmaceuticals Inc., a New Jersey-based pharmaceutical company, announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).

Lilly is investing $700 million to build a state-of-the-art facility in the Boston Seaport, as part of plans to advance the company’s RNA-based research and development activities. 

Roivant Sciences launched the new subsidiary Hemavant, which hit the ground running with a licensing agreement from Eisai for RVT-2001, a potential first-in-class small molecule SF3B1 modulator.

Calcium

After generating 30 percent growth during 2021, Calcium announced the launch of Vitamin MD, a new division dedicated to providing leading edge medical education solutions.

Takeda

With two assets licensed from Takeda, Oak Hill Bio launched with a focus on developing therapeutics for patients and extremely preterm infants who are suffering from rare autoimmune diseases.

Domestic violence nonprofits Safe in Harm’s Way Foundation Inc. and DomesticShelters.org, a service of Theresa’s Fund, are partnering with IPG Health company Neon and the Out of Home Advertising Association of America (OAAA) to continue raising nationwide awareness of domestic abuse. Experts say the COVID-19 crisis prompted a shadow pandemic or uptick in domestic abuse and the campaign aims to connect victims of abuse with the help they need through out of home advertising.